Challenging the current paradigms for clinical immunogenicity testing — the pros and cons Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Christopher Tiedje, BioAgilytix Lydia Michaut, Novartis
10:15
Coffee Break
10:45
Continue“Challenging the current paradigms for clinical immunogenicity testing — the pros and cons”
12:15
Lunch Break
13:30
Bring Your own Problems (Break out Sessions) Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Sofie Pattijn, IQVIA Noel Smith, Lonza Sophie Tourdot, Pfizer Tim Hickling, Roche ydia Michaut, Novartis
15:00
Coffee Break
15:30
Continue“Bring Your own Problems (Break out Sessions)”
16:30
Closing of the Workshop Day
17:00
18:30
Meeting of the EIP Working Groups Members of EIP working groups
Tuesday, February 25th 2025
09:00
Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi
09:15
Spotlight Presentations: Machine Learning and Immunogenicity: Perspectives on the use of AI in Risk Assessment and Mitigation Daniel Leventhal, Xaira Therapeutics
Session 2: Prediction of Immunogenicity Chair: Sebastian Spindeldreher
10:15
EIP NCIRA Working Group Update Sebastian Spindeldreher, Integrated Biologix on behalf of EIP
10:30
Analyzing and decreasing the immunogenicity potential of biotherapeutics using in silico approaches Michael Gutknecht, Novartis
11:00
Coffee Break
11:30
Enhancing Large Molecule Design by Early Integration of MAPPs using Defined Allele Antigen Presenting Cells Andreas Hollenstein, Roche
12:00
The localization of T-cell epitopes in biopharmaceuticals: from peptides to gene therapy vectors Bernard Maillere, University Paris-Saclay
12:30
Lunch Break
13:30
Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity Michel Siegel, Roche
14:00
Aggregation of therapeutic antibodies enhances dendritic cell uptake and T-cell responses Marc Pallardy, University Paris Saclay
14:30
Suitable peptide controls for screening generic peptide products in adaptive immunogenicity assays Chloë Ackaert, IQVIA Laboratories In Vitro Immunology (FKA ImmunXperts)
15:00
Coffee Break
Session 3: Immunogenicity Assays Chair: Arno Kromminga
15:30
EIP Immunogenicity Assays Working Group Update Linlin Luo, Merck Sharp & Dome on behalf of EIP
15:45
Current industry practices for in-study cut point setting for clinical immunogenicity assays Riejanne Bax-Seigers, ICON
16:15
Comparing Signal-to-Noise with titer results – a retrospective analysis Karin Benstein, Sanofi
16:45
Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the clinical support of a bispecific therapeutic antibody Saskia van der Lee, Genmab
Session 3: Social Event Chair: Barbara Vercruyssen
18:00
Get Together
23:00
Good Night
Wedneday, February 26th 2024
Session 4: Immunogenicity Assays continued Chair: Arno Kromminga
09:00
Fit-for-purpose non-clinical immunogenicity assessment to support PK data interpretation – a case study Christopher Tiedje, BioAgilytix
09:30
Evaluating and Mitigating Pre-existing Anti-Drug Antibodies of Bi-Specific Therapeutic Proteins in Early Drug Discovery: A Roche Case Study Janine Faigle, Roche
Short Talks (15 min)
10:00
A retrospective analysis of clinical immunogenicity data – time for singlicate change? Sandra Ribes Miravet, Sandoz
10:15
Is ADA-tiered approach suitable to therapeutics with pre-existing antibodies? Issa Jyamubandi, Intertek
10:30
Coffee Break
11:00
Generation of anti-drug antibody (ADA) positive control and development of a bridging immunogenicity assay for RNA therapeutics in human serum Gnana Oli Rajaraman, AiCuris Anti-infective Cures AG
11:15
Application of SPR technology for assessment of immunogenicity of a dual-peptide cancer vaccine Daniel Worms, BioAgilytix
11:30
In-depth characterization and semi-quantification of ADAs using innovative hybrid LC-MS methods to support clinical development of biotherapeutics Stéphane Muccio, Sanofi
Session 5: Clinical Relevance of Immunogenicity Chair: Lydia Michaut
11:45
Analysis of Clinical Immunogenicity Data for a Multi-Study Program Susan Irvin, Regeneron
12:15
The effects of the immune modulator methotrexate on anti-drug antibody formation Floris Loeff, Sanquin
12:45
Lunch Break
13:45
An American Association of Pharmaceutical Scientists (AAPS) Perspective on Clinical Relevance of Immunogenicity Mohsen Rajabi, Novartis (on behalf of AAPS)
Session 5: Immunogenicity of Novel Modalities Chair: Noel Smith
14:15
Success in treatment of cancer and autoimmunity with CAR T-cells: application to prevention and mitigation of immunogenicity of therapeutic proteins? Amy Rosenberg, Epivax
14:45
Exploring alternatives to the 3-tiered immunogenicity testing paradigm for gene therapy programs Robert Nelson, BioAgilytix
15:15
Cell-Based Assays for Neutralizing Antibodies: From Gene Therapy to Immune Effector Functions Michael Tovey, Svar Life Science
Session 6: Regulatory Chair: Daniel Kramer
15:45
Future impact of immunogenicity data on Biosimilar developments René Anour, Pfizer
16:15
Conference Summary & Outlook by the EIP Chairman Daniel Kramer, Sanofi